TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11758701

Group type: EXPERIMENTAL
Intervention: Neutralization instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No neutralization instruction
Number of subjects: 0
Study: 9156108

Group type: EXPERIMENTAL
Intervention: Frenchay Aphasia Screening Test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Request to write 'name and address'
Number of subjects: 10
Study: 7892971

Group type: EXPERIMENTAL
Intervention: 0.25% plain bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 42
Study: 3657889

Group type: EXPERIMENTAL
Intervention: 30 mg of aspartame per kilogram of body weight
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 40
Study: 29902133

Group type: EXPERIMENTAL
Intervention: MMR-RIT vaccine (Priorix, GSK)
Number of subjects: 869

Group type: COMPARATOR
Intervention: MMR II vaccine (control; M-M-R II, Merck&Co Inc.)
Number of subjects: 869
Study: 28298558

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 165
Study: 26285695

Group type: EXPERIMENTAL
Intervention: rATG (Thymoglobulin®)
Number of subjects: 183

Group type: COMPARATOR
Intervention: basiliximab
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: rATG
Number of subjects: 183
Study: 23059130

Group type: EXPERIMENTAL
Intervention: Electrical coupling information (ECI) available
Number of subjects: 40
Study: 21062996

Group type: EXPERIMENTAL
Intervention: Serp-1 (5 μg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serp-1 (15 μg/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound
Number of subjects: 48
Study: 18187530

Group type: EXPERIMENTAL
Intervention: MK-0343 0.75 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MK-0343 0.25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17010856

Group type: EXPERIMENTAL
Intervention: Conventional capsular tension ring (CTR)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Closed foldable equator ring (CFER)
Number of subjects: 70
Study: 14732977

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: PVP chemotherapy
Number of subjects: 34
Study: 11032585

Group type: EXPERIMENTAL
Intervention: Tamoxifen therapy
Number of subjects: 159
Study: 9014295

Group type: COMPARATOR
Intervention: DHEAS, 50 mg po bid for 4 days, administered as an adjuvant to tetanus vaccination.
Number of subjects: 133

Group type: COMPARATOR
Intervention: DHEAS administered immediately before and 24 hours after influenza vaccination.
Number of subjects: 133
Study: 1362613

Group type: EXPERIMENTAL
Intervention: Cysteine (200 mg 4 times daily)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: MMSC (500 mg 4 times daily)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) and Cysteine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) and MMSC
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily) alone
Number of subjects: 138
Study: 3161176

Group type: EXPERIMENTAL
Intervention: 0.3% foscarnet cream
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 86
Study: 29578732

Group type: EXPERIMENTAL
Intervention: Threat condition (low masculinity feedback, n = 22)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control condition (high masculinity feedback, n = 22)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Undermine condition (low masculinity feedback with undermining information, n = 21)
Number of subjects: 65
Study: 27998448

Group type: COMPARATOR
Intervention: docetaxel/cisplatin (Control)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin (Arm 1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: docetaxel/cisplatin (Arm 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: docetaxel alone (Arm 3)
Number of subjects: 124
Study: 24758167

Group type: EXPERIMENTAL
Intervention: Be smart against cancer (BSAC) program
Number of subjects: 235

Group type: COMPARATOR
Intervention: Wait-control group
Number of subjects: 235
Study: 22024203

Group type: EXPERIMENTAL
Intervention: Web-based interactive module
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional methods (Control)
Number of subjects: 36
Study: 20702806

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; 0.5 l/day; 5.2 mmol of NO(3)(‐)/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR)
Number of subjects: 8
Study: 18469091

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Esomeprazole (ESO) 20 mg once daily (can be increased to 40 mg once daily or 20 mg twice daily)
Number of subjects: 554
Study: 15939025

Group type: EXPERIMENTAL
Intervention: Speeded response procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process dissociation procedure
Number of subjects: 0
Study: 12014516

Group type: EXPERIMENTAL
Intervention: 2 IU/m2/day of growth hormone (GH)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 4 IU/m2/day of growth hormone (GH)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-dose group (2 IU/m2/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-dose group (4 IU/m2/day)
Number of subjects: 29
Study: 10081129

Group type: COMPARATOR
Intervention: Sublingual glycine application in daily dose of 1-2 g for 5 days, starting within the first 6 hours of stroke development.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study: 7583388

Group type: EXPERIMENTAL
Intervention: Cessation of antibiotics regardless of ANC; initial treatment with ceftazidime +/- vancomycin for a median length of treatment of 3 days
Number of subjects: 32
Study: 2246580

Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 50
Study: 462159

Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Primary radiotherapy
Number of subjects: 36
Study: 31422924

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for CABG
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for PCI
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for renal failure in CABG
Number of subjects: 1858

Group type: EXPERIMENTAL
Intervention: Society of Thoracic Surgeons (STS) risk scores for renal failure in PCI
Number of subjects: 1858
Study: 31064965

Group type: EXPERIMENTAL
Intervention: Daily life-based physical activity enhancement program with one-on-one counseling, customized text messages, exercise diary, and mobile pedometer for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 58
Study: 28267011

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol with ascorbic acid
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oral sulfate solution
Number of subjects: 167
Study: 26554839

Group type: EXPERIMENTAL
Intervention: Perinatal home-visiting program using psychologists
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 440
Study: 23045243

Group type: EXPERIMENTAL
Intervention: Moderate/severe patellofemoral osteoarthritis (PFOA)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Moderate/severe PFOA
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mild PFOA
Number of subjects: 167
Study: 20500120

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 35
Study: 19303137

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily for 1 year
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg
Number of subjects: 713
Study: 17540908

Group type: EXPERIMENTAL
Intervention: Information programme
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 742

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 742
Study: 11057005

Group type: EXPERIMENTAL
Intervention: Time pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invalid cue validity (S1)
Number of subjects: 0
Study: 8647360

Group type: EXPERIMENTAL
Intervention: Oral etoposide (n = 18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Parenteral etoposide (n = 18)
Number of subjects: 36
Study: 1596044

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin (DR) combination therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Doxycycline-streptomycin (DS) combination therapy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin (DR) combination therapy excluding spondylitis patients
Number of subjects: 95

Group type: COMPARATOR
Intervention: Doxycycline-streptomycin (DS) combination therapy excluding spondylitis patients
Number of subjects: 95
Study: 6208807

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5% plasmaprotein solution (PPS)
Number of subjects: 9
Study: 30125349

Group type: EXPERIMENTAL
Intervention: MK-2640
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 16
Study: 30191370

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 0
Study: 26135689

Group type: EXPERIMENTAL
Intervention: Dukes' A colorectal cancer
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Dukes' B colorectal cancer
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Dukes' C colorectal cancer
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Right colon tumors
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Left colon tumors
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Rectal tumors
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Initial stage influence on postrecurrence survival
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Site of primary influence on postrecurrence survival
Number of subjects: 1537
Study: 24909625

Group type: EXPERIMENTAL
Intervention: Carrier frequency of 500 Hz, modulated at 40 Hz, intensity of 95 dBA
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Carrier frequencies of 250, 500, and 1000 Hz, modulated at 20, 37, 40, 43, 70, 77, and 80 Hz, intensity of 95 dBA
Number of subjects: 83

Group type: COMPARATOR
Intervention: Group of normal hearers
Number of subjects: 83
Study: 22843115

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) (4 × 5‐min 220 mm Hg bilateral leg occlusion)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (C) (4 × 5‐min 20 mm Hg bilateral leg occlusion)
Number of subjects: 13
Study: 20189927

Group type: EXPERIMENTAL
Intervention: Concord grape juice (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Number of subjects: 77
Study: 18758386

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole 18 mg/kg twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 16190387

Group type: EXPERIMENTAL
Intervention: Ulinastatin 1.2 x 10(4) U/kg (half dose intravenously after induction, half in primary solution)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ulinastatin 1.2 x 10(4) U/kg
Number of subjects: 22
Study: 12208645

Group type: EXPERIMENTAL
Intervention: Sustained-release ascorbic acid (3000 mg/day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 10624701

Group type: EXPERIMENTAL
Intervention: Serum α-tocopherol
Number of subjects: 204
Study: 8786878

Group type: EXPERIMENTAL
Intervention: Nonsurgical management strategies for uterine fibromyomata
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative temporizing measures
Number of subjects: 0
Study: 1957553

Group type: EXPERIMENTAL
Intervention: GHRH(1-29)NH2 with TRH
Number of subjects: 10

Group type: COMPARATOR
Intervention: TRH alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GHRH alone
Number of subjects: 10
Study: 30511292

Group type: EXPERIMENTAL
Intervention: Diario della Salute program
Number of subjects: 2630

Group type: COMPARATOR
Intervention: Regular curriculum (Control)
Number of subjects: 2630
Study: 28730886

Group type: EXPERIMENTAL
Intervention: 10 m incremental shuttle walk test (ISWT)
Number of subjects: 15
Study: 25980582

Group type: EXPERIMENTAL
Intervention: Daily tailored text messaging for 90 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study: 24820711

Group type: EXPERIMENTAL
Intervention: Calcium sulfate (CaS) placed into the postextraction sockets
Number of subjects: 30

Group type: COMPARATOR
Intervention: Obliterative suture only
Number of subjects: 30
Study: 22441104

Group type: EXPERIMENTAL
Intervention: Individualized treatment group (ITG) with Peg IFNa-2a and ADV
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment group (STG) with Peg IFNa-2a monotherapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Individualized treatment group (ITG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment group (STG)
Number of subjects: 160
Study: 20430207

Group type: EXPERIMENTAL
Intervention: Reduced CsA blood level (RE group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard CsA blood level (SE group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 18575222

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 202

Group type: COMPARATOR
Intervention: Tazarotene 0.1% cream
Number of subjects: 202
Study: 15855501

Group type: EXPERIMENTAL
Intervention: Alamifovir single doses (0.2 to 80 mg), subset receiving 20 mg in a fed state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alamifovir multiple doses (2.5 to 15 mg twice daily for 15 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food intake (fed state)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alamifovir and its metabolites
Number of subjects: 0
Study: 14563518

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 0
Study: 10471425

Group type: EXPERIMENTAL
Intervention: Atherothrombotic strokes
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Cardioembolic strokes
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Strokes of other/unknown mechanism
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Lacunar strokes
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Overall infarcts
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: Correlation between stroke subtype and time of symptom onset
Number of subjects: 1272
Study: 8951781

Group type: EXPERIMENTAL
Intervention: 32P alone
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: 32P with hydroxyurea maintenance
Number of subjects: 682

Group type: COMPARATOR
Intervention: Non radio-mimetic agents (hydroxyurea or pipobroman)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: 32P-treated cases (excluding skin cancers)
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: 32P and hydroxyurea as maintenance
Number of subjects: 682

Group type: COMPARATOR
Intervention: Non radio-mimetic agents (hydroxyurea or pipobroman) in relatively young cases
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 682

Group type: COMPARATOR
Intervention: Pipobroman-treated cases
Number of subjects: 682
Study: 1937996

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg) given i.v. 1, 2 and 3 h before surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no ciprofloxacin)
Number of subjects: 24
Study: 6754067

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF
Number of subjects: 52
Study: 30472195

Group type: EXPERIMENTAL
Intervention: Mandibular digital model (DM) registration using the mucogingival junction as the reference
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mandibular digital model (DM) registration
Number of subjects: 12
Study: 28054966

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened coffee
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Reduced-energy orange juice (OJ)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Low-fat milk (LFM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Water
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fat-free milk
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 46
Study: 24423575

Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention for heavy drinkers
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 103
Study: 23672851

Group type: EXPERIMENTAL
Intervention: High carbohydrate breakfast (335 kcals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High fiber breakfast (360 kcals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skipping breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal carbohydrate breakfast consumed ad libitum
Number of subjects: 0
Study: 21378581

Group type: EXPERIMENTAL
Intervention: Castile soap solution
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High-pressure pulsatile lavage
Number of subjects: 111

Group type: COMPARATOR
Intervention: Low-pressure pulsatile lavage
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Functional outcome scores (EuroQol-5 dimensions and short form-12)
Number of subjects: 111
Study: 19766213

Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 0
Study: 17927463

Group type: EXPERIMENTAL
Intervention: Telephone intervention (nurse-initiated call)
Number of subjects: 6106

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 6106
Study: 16107485

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 4809

Group type: EXPERIMENTAL
Intervention: Tirofiban (in patients with ACS)
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Abciximab (in patients with ACS)
Number of subjects: 4809

Group type: EXPERIMENTAL
Intervention: Tirofiban (in patients without ACS)
Number of subjects: 4809

Group type: COMPARATOR
Intervention: Abciximab (in patients without ACS)
Number of subjects: 4809
Study: 12511182

Group type: EXPERIMENTAL
Intervention: Serum IGFBP-3
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum albumin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum cholinesterase
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum prealbumin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum AST
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum ALT
Number of subjects: 51
Study: 9430592

Group type: EXPERIMENTAL
Intervention: Light pulses presented to the popliteal region (behind the knee)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of body temperature and melatonin concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implications for treatment development
Number of subjects: 0
Study: 8132134

Group type: EXPERIMENTAL
Intervention: 3 x 100 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3 x 200 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3 x 500 micrograms octreotide subcutaneously per day for 10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study: 2818278

Group type: EXPERIMENTAL
Intervention: Topical timolol therapy (twice daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 1205846

Group type: EXPERIMENTAL
Intervention: Three different oil bath products at increased concentrations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increased concentrations of oil bath products
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bath water temperature increased from 32 degrees to 38 degrees C
Number of subjects: 30
Study: 27780887

Group type: EXPERIMENTAL
Intervention: Pre-exercise music intervention
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implementation intentions (writing down 'if … then …' sentences)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 50
Study: 27812689

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel (ACT)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab (ACTH)
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Trastuzumab in patients with FCGR3A-158V/V or FCGR3A-158V/F genotypes
Number of subjects: 1251
Study: 25467566

Group type: EXPERIMENTAL
Intervention: LUCAS‐2 mechanical chest compression
Number of subjects: 4471

Group type: COMPARATOR
Intervention: Manual CPR (control)
Number of subjects: 4471
Study: 23222289

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg, 2 capsules)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (2 capsules)
Number of subjects: 200
Study: 21631929

Group type: EXPERIMENTAL
Intervention: Roflumilast (500 μg tablet once daily; Day 2-18) and concomitant formoterol (24 μg twice daily; Day 12-18)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Formoterol (24 μg twice daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Roflumilast and formoterol administered concomitantly
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Roflumilast and formoterol administered individually
Number of subjects: 27